The U.S. Food and Drug Administration (FDA) is researching data that shows an increased risk of cancer, in diabetic patients who use Regranex Topical Gel (becaplermin) for the treatment of foot and leg ulcers.
The FDA received information from a study that was performed to investigate the possibility of increased cancer risk in connection with use of Regranex.
The study was based on diabetic patients who are at least 19 years of age, with no history of cancer and prescribed Regranex or not.
While there is not conclusive evidence at this time to decide there is an increase in the number of patients that develop cancer, there is considerable danger to diabetics leaving foot ulcers untreated. The potential risks of using Regranex should be considered against the benefits.
The FDA suggests patients discussing the pros and cons of Regranex use with their medical doctors.